01 — At a Glance
The Pesticide Company Nobody’s Heard Of But China Has
Bhagiradha Chemicals just posted Q3 FY26 revenue of ₹114 crore with PAT of ₹4.62 crore. EBITDA grew 49% year-on-year. The stock has crashed 37% in one year, yet somehow still trades at 177x P/E — a number so absurd it could only happen in the Indian stock market. To put this in perspective: you’re paying ₹177 for every rupee of annual profit. A Tier-2 agrochemical company. Backed by ₹189 crores in debt. Building a ₹800 crore factory it’s not entirely sure how to finance. And yet, there it sits.
- 52-Week High / Low₹331 / ₹180
- Q3 FY26 Revenue₹114 Cr
- Q3 FY26 PAT₹4.62 Cr
- TTM EPS₹1.02
- Annualised EPS (Q1-Q3 Avg × 4)₹1.40
- Book Value / Share₹53.2
- Price to Book3.39x
- Gross Margin (Q3)43.0%
- EBITDA Margin (Q3)12.0%
- Debt (Dec 2025)₹189 Cr
The Plot Twist: Bhagiradha’s parent company — itself — is essentially bankrolling a wholly-owned subsidiary called Bheema Fine Chemicals, pouring ₹800+ crores into a greenfield expansion that “should generate 5x revenue in 6-7 years.” That’s not a target. That’s a hope. That’s Diwali without the fireworks, just a bunch of guys crossing fingers. The Bheema facility Phase 1 just started December 2025. It’s already running late. It’s already over budget by ₹700 crores. And somehow, the rating agency still gave it an IND BBB+. Very interesting.
02 — Introduction
The Agrochemical Story Nobody Asked For (But Here We Are)
In 1993, a scientist named S. Koteswara Rao — genuinely qualified, IIT Madras background, worked in Germany for Chemische Werke Huels — decided to come back to India and make pesticides. Not because it was fashionable. Not because he saw a five-year wealth-creation thesis. But because India’s farmers were using whatever was available, and he thought he could make something better.
Thirty-two years later, his company, Bhagiradha Chemicals, manufactures 32 different active ingredients — insecticides, fungicides, herbicides — and sells them to other agrochemical companies who slap their own labels on top and sell them to you. The irony: Bhagiradha is invisible. You’ve never heard of it. But your wheat, your cotton, your vegetables — probably got sprayed with one of their molecules.
Fast forward to Q3 FY26: the company posted ₹114 crore in revenue. EBITDA of ₹13.7 crore, growing 49% YoY. Gross margins at 43%. The Bheema expansion facility in Karnataka just started operations in December 2025. By the time this facility reaches full capacity, the company is supposed to be making ₹2,200 crores in revenue (they claim). That’s 5x from today. In 6-7 years. Without any new molecules approved globally. Without any new customer contracts signed. Just… scale and luck.
The Ind-Ra Rating Update (March 2026): Ind-Ra revised the outlook on BCIL’s bank facilities to Stable (from Positive), affirmed the rating at IND BBB+. Translation: the credit story is no longer “getting better.” It’s “holding steady.” Which is code for: “We’re watching very closely to see if this ₹800 crore bet doesn’t blow up.” That’s not bullish. That’s cautious.
03 — Business Model: Who Actually Needs This Company?
They Make The Poison. Someone Else Sells The Poison. Repeat.
Members get full access to every article.
